Kornimate/medical-research-clean huggingface dataset:
effects of upper extremity-focused neuromuscular training in people with multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the effectiveness of upper extremity focused neuromuscular exercise training in early stage people with ms will be investigated. people with ms enrolled in the study will be randomly assigned to three groups: neuromuscular exercise group (neg), conventional exercise group (ceg), and control group (cg). all three groups will be assessed with primary and secondary outcome measures at baseline, week 8, and week 12. neg, ceg, and cg will be initially assessed for upper extremity function, cognitive function, lower extremity function, grip strength, proximal muscle strength, sensation, coordination, fatigue, postural sway, and core muscle strength and endurance. then, neg will receive clinically supervised upper extremity focused neuromuscular exercise training with a minimum of 60 minutes of session time, 2 days a week for 8 weeks. this exercise training includes steps for postural control, weight transfer, proximal and distal muscle strengthening, proprioception, coordination and reaction speed. similarly, ceg will receive clinically supervised traditional upper extremity exercise training, twice a week for 8 weeks, with a minimum of 60 minutes of session time. this exercise training includes strengthening with the band and manuel dexterity exercises. in both groups, stretching and mobility exercises will be added to the warm-up and cool-down exercises before and after the program. during this process, cg will be on the waiting list. at the end of 8 weeks, all three groups will be re-evaluated. after the exercise training, follow-up will be done and evaluations will be repeated in the 12th week. this study will provide evidence on the effects of upper extremity-focused neuromuscular exercise training on physical and cognitive functions in early-stage people with ms compared to traditional treatment approaches.


Eligibility criteria:
inclusion criteria: * definite ms according to mcdonald criteria, * 18-64 years * rrms, * edss \< 4, * minimal or moderate upper extremity involvement exclusion criteria: * having an attack in the last three months, * mini mental test \<24 or visual deficit, * other medical conditions accompanying ms (cardiac, orthopedic or rheumatic, etc.), * being pregnant or breastfeeding, * doing regular exercise - receiving physiotherapy, * having spasticity of 2 or more in the upper extremity

Keywords: multiple sclerosis exercise function upper extremity neuromuscular exercise training manual dexterity
effects of post-stroke upper extremity assistance

Conditions: Arm Weakness as a Consequence of Stroke

Summary: the purpose of this study is to quantify the improvement of post- stroke individuals' ability to move their arms during and after robot assisted therapy. while researchers know that robot assisted therapies improve motor performance over the course of weeks, they do not know how motor performance is affected over the course of minutes or hours. a better understanding of how robot assisted therapies affect motor performance on short time scales may help us to prescribe more effective therapy doses to maximize motor recovery after neurological injury. the study will allow us to obtain a detailed understanding of the performance of the device as described above.


Eligibility criteria:
inclusion criteria: * greater than 6 months post-stroke * passive abduction to 90 degrees at shoulder * reduced active (retro)flexion/extension at shoulder when abducted at 90 degrees * reduced active flexion/extension at elbow exclusion criteria: * unable to give informed consent * unable to comprehend and follow instructions * have a condition (other than stroke) affecting sensorimotor function * show evidence of unilateral spatial neglect * unable to sit in a chair without armrests for 2 hours
digital interventions for detection and reduction of moral distress

Conditions: Moral Injury; Distress, Emotional

Summary: stress, anxiety, distress and depression are exceptionally high among healthcare workers at the frontline of the covid-19 pandemic. factors underlying distress and resilience are unknown and there are no evidence based interventions to impact the mental wellbeing of frontline healthcare workers. this study will evaluate a novel virtual reality platform to gather the "distress experience" of frontline healthcare workers at unity health toronto in real time during the ongoing covid pandemic by developing and showing feasibility of digital technology (virtual reality (vr) and mobile app) as a digital platform to understand the causes and ultimately reduce the moral distress of healthcare providers during the covid-19 pandemic. the project will develop innovations which can be used for future pandemics and other contexts prone to producing moral distress and injury.


Eligibility criteria:
inclusion criteria: * staff or healthcare providers working at unity health toronto * 18 years of age or older * must own a mobile phone running android version 6.0 and higher, or an iphone 6 running os 14 and higher) exclusion criterion: - non-unity health toronto staff

Keywords: depression anxiety stress moral injury moral distress loneliness
glutathione and its precursors in hiv-infected patients

Conditions: HIV Infection

Summary: the aim of this study is to investigate the responses of the serum amyloid a (saa) pathway to dietary supplements of glutamine (gln) and cysteine (cys) together with methionine (met)-overloading in hiv+ patients comparatively to healthy controls.

introduction: among the 4 sulphur-containing amino acids (saa), only met and cys are incorporated into proteins, but hcy and tau are related to oxidative stress and glutathione (gsh), the major intracellular hydro-soluble anti-oxidant agent. hiv+ patients present low levels of antioxidant nutrients, including gsh and its precursors. objective: to investigate the responses of the saa pathway to dietary supplements of gln and cys together with met-overloading in hiv+ patients comparatively to healthy controls. methods: twelve hiv+ (6 males and 6 females, 25-36 yrs old) patients under haart (one hiv protease inhibitor in combination with two nucleoside analogs) for at least one year and 20 (10m and 10f, 23-28 yrs old) healthy controls were randomly assigned to 7-day diets containing either nac (n-acetylcysteine, 1g/d) or gln (20g/d), with a 7-day washout period with their usual diet (ud). blood samples were drawn after overnight fast before and after (2h and 4h) ingesting the met (100 mg/kg) overload (met-ol) with determination of the area under the curve (auc). hplc plasma analysis of saa (met, hcy, cys and tau), gsh and gssg and ser, gly, glu and gln was carried out at moments before (mo) and after 7-day diets (m1). additionally, at baseline, both groups were assessed for anthropometry (bmi, kg/m2; body fat %) and plasma biochemistry (creatinine, urea, γ-glutamyl transpeptidase, glucose, triglycerides, cholesterol, uric acid, albumin, folic acid and vitamin b12).the hiv+ group (g2) was also characterized by the viral load, cd4+ and cd8+ lymphocytes counts. statistical comparisons were undertaken among diets between groups with p = 0.05.

Eligibility criteria:
inclusion criteria: * hiv infection * antiretroviral therapy for at least one year exclusion criteria: * presence of any renal or liver failure * ingestion of either vitamins b or gsh precursors
thyroid autoimmunity and reproductive failure in danish women

Conditions: Thyroid; Infertility; Autoantibodies; Autoimmunity; Pregnancy Loss

Summary: the present ph.d.-study investigates the mechanisms behind the association between thyroid autoimmunity and reproductive failure.


Eligibility criteria:
inclusion criteria: * women followed in the fertility clinic exclusion criteria: * pregnancy at time of blood sampling. immune-suppressive ⁄modulatory treatments. women referred for oocyt donation, genetic testing, and hepatitis and hiv-positivity

Keywords: thyroid infertility autoimmunity pregnancy loss autoantibodies
monitoring the hematological toxicity of drugs (hematox)

Conditions: Hematological Abnormality; Hematotoxicity

Summary: several drugs and chemotherapies seem to have an impact on the hematological system. this study investigates reports of hematological toxicities, including the international classification of disease icd-10 for treatments in the world health organization (who) global individual case safety report (icsr) database (vigibase).

several drugs and chemotherapies seem to have an impact on the hematological system and are responsible of a wide range of hematological side effects. those are poorly described, due to the modification of the pharmacopeia, and the recent recognition of several of these adverse events. this study investigates the main characteristics of patients affected by rare hematological side effects imputed to drugs. a causality assessment according to the who-umc (world health organization - uppsala monitoring center) is systematically applied.

Eligibility criteria:
inclusion criteria: * case reported in the who's pharmacovigilance database till 01/02/2019 exclusion criteria: * chronology not compatible between the drug and the toxicity

Keywords: advrese event hematotoxicity drugs chemotherapies
immuno-monitoring of patients with metastatic melanoma (ajcc stadium iv) under chemotherapy

Conditions: Immuno-monitoring

Summary: this pilot clinical trial aims at evaluating immuno-modulating effects of palliative treatment with specifically dosed standard chemotherapeutics in patients with metastatic melanoma (ajcc stage iv) by assessing myeloid-derived suppressor cells' (mdscs) count and activity.


Eligibility criteria:
inclusion criteria: * histologically defined metastatic melanoma patients (ajcc stage iv) * aged 18 to 80 years * at least one prior systemic anti-melanoma therapy; if brafv600 positive, at least one prior brafi therapy exclusion criteria: * therapy-naive patients * any contra-indications for (specific) systemic chemotherapy
bendamustine as second-line therapy in treating patients with relapsed or refractory small cell lung cancer

Conditions: Lung Cancer

Summary: rationale: drugs used in chemotherapy, such as bendamustine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. purpose: this phase ii trial is studying how well bendamustine works as second- or third-line therapy in treating patients with relapsed or refractory small cell lung cancer.

objectives: primary * to determine the time to progression in patients with relapsed or refractory small cell lung cancer treated with second- or third-line bendamustine. secondary * to determine the toxicity of this drug in these patients. * to determine the response rate, progression-free survival, and overall survival of patients treated with this drug. outline: this is a multicenter study. patients receive bendamustine iv over 1 hour on days 1 and 2. treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. after completion of study treatment, patients are followed up every 6-8 weeks.

Eligibility criteria:
disease characteristics: * histologically or cytologically confirmed small cell lung cancer * relapsed or refractory disease after 1-2 prior chemotherapy regimens * measurable disease * ecog - eastern cooperative oncology group performance status 0-2 * anc ≥ 1,500/mm³: anc = absolute neutrophil count * platelet count ≥ 100,000/mm³ * hemoglobin ≥ 9 g/dl * bilirubin normal * ast/alt ≤ 2 times upper limit of normal (uln) (≤ 5 times uln in patients with hepatic metastases; ast/alt = alanine transaminase (alt) and aspartate aminotransferase (ast) * creatinine clearance \> 40 ml/min * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception before, during, and for ≥ 3 months after completion of study therapy * no known hypersensitivity to bendamustine * no other malignancy for which the patient has been treated within the past year except for nonmelanoma skin cancer or carcinoma in situ of the cervix * no cardiac disease, including any of the following: * unstable angina pectoris * life-threatening cardiac arrhythmia * symptomatic congestive heart failure * no uncontrolled infection * no other concurrent chemotherapy, immunotherapy, or anti-tumor hormonal therapy

Keywords: recurrent small cell lung cancer
a study of tl-925 for the treatment of allergic conjunctivitis

Conditions: Allergic Conjunctivitis

Summary: in this prospective phase 2, single-center, randomized, double-masked, placebo-controlled study, approximately 70 subjects with allergic conjunctivitis will be randomized 1:1 to receive either tl-925 or placebo as topical ophthalmic eye drops administered bilaterally. the study comprises of a screening and treatment period using the conjunctival allergen challenge model to evaluate tl-925 for the treatment of allergic conjunctivitis.


Eligibility criteria:
inclusion criteria: * individuals aged 18 years or older * female subjects of childbearing potential and their male partners must both use a highly effective contraception method during the study. * documented history of ocular allergies and a positive skin test reaction to a seasonal (grass, ragweed, tree pollen) or perennial (cat dander, dog dander, dust mites, cockroach) allergen as confirmed by an allergic skin test conducted at visit 1 or within the past 60 months. * calculated best-corrected visual activity of 0.7 logmar or better * positive bilateral cac reaction exclusion criteria: * any systemic or ocular disease currently producing ocular redness and/or ocular discomfort, or that may interfere with the conduct of the study. * any ocular surgical intervention within the last 3 months or refractive surgery within the last 6 months * any ongoing ocular infection (bacterial, viral or fungal)

Keywords: tl-925 phase ii
real-life evaluation of the daivobet® gel applicator

Conditions: Plaque Psoriasis

Summary: this study aims to describe the patient population being treated and evaluate their treatment adherence and treatment outcomes during treatment of scalp psoriasis with daivobet® gel applicator for 4 weeks.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * dermatologist or general practitioner has decided to initiate treatment with daivobet® gel applicator exclusion criteria: * indication not within the approved labelling in france * contraindication for treatment with calcipotriol or betamethasone dipropionate * informed consent to participate in the study has not been obtained

Keywords: psoriasis vulgaris, scalp, topical, applicator, device
role of tyrosine kinase lyn and cleaved form by caspases in psoriasis

Conditions: Psoriasis; Atopic Dermatitis

Summary: psoriasis is a chronic autoimmune disorder of the skin. in this disease, the inflammatory caspases, cysteine proteases involved in the processing of many proteins, are activated. transgenic mice expressing the cleaved form of caspases by lyn, a tyrosine kinase src family, develop an inflammatory syndrome with the characteristics of human psoriasis. to clarify the relationship between the cleaved form of lyn by caspases and psoriasis, the investigators intend to develop a clinical study to analyze the expression, cleavage and activity of lyn and the activation of caspases from skin biopsies of patients with this disease. this study will be conducted on a cohort of patients with different forms of psoriasis (plaque, pustular and erythrodermic) and atopic dermatitis, another skin disorder associated with chronic inflammation. thus, the investigators will evaluate the expression and activity of lyn from skin lesion (l) and non-lesional (nl) from the same patient in parallel with the level of caspase activation and apoptotic inflammatory. thus, the investigators will verify that the cleavage by caspases of lyn is associated specifically with psoriasis, as the investigators believe, or more generally to the skin inflammation. the investigators work would then define the cleavage by caspases of lyn as a new potential marker of human psoriasis.


Eligibility criteria:
inclusion criteria: psoriasis arms: * plaque psoriasis and erythrodermic more than 10% of body surface area. * pustular psoriasis of at least 1% of body surface. * atopic dermatitis arm:patients with atopic dermatitis has been identified and inflammatory lesions on the skin. * healthy arm:people not suffering from any skin disease exclusion criteria: * systemic treatment of psoriasis for at least 4 weeks and / or local treatment for at least 2 weeks at the time of study entry. * patient with significant infection and / or immunocompromised.
rectal misoprostol versus sublingual misoprostol prior to myomectomy

Conditions: Bleeding During Myomectomy

Summary: the aim of the study is to compare the effectiveness of rectally administered prostaglandin e1 synthetic analogue (misoprostol) 400 microgram versus sublingually administered misoprostol before myomectomy to decrease blood loss during and after the operation.


Eligibility criteria:
inclusion criteria: * patients presenting for abdominal myomectomy with documented uterine fibroids on pelvic imaging * age ≥ 18 years and ≤ 50 years * pre-operative hemoglobin \>8 g/dl * ability to understand and the willingness to sign a written informed consent. * admissible medical/surgical history * five or less symptomatic uterine myomas * all myomas are subserous or intramural. * uterine size less than 24 weeks pregnancy exclusion criteria: * patients who have had a prior abdominal myomectomy * post-menopausal women * patients with known bleeding/clotting disorders * patients with a history of gynecologic malignancy * hypertension. * cardiac and pulmonary diseases. * obesity (body mass index \> 30 kg/m2). * history of allergic reactions attributed to misoprostol * cases that will require intraoperative conversion of myomectomy to hysterectomy.
changes in selected function- and participation-related characteristics in post-covid patients following pneumological phase ii rehabilitation

Conditions: Post-COVID-19

Summary: the aim of this project is to provide insight into the relatively new group of post-covid patients. on the basis of data collected in routine practice, function- and participation-related patient characteristics of post-covid patients are first described descriptively. subsequently, the extent to which selected function- and participation-related parameters change following a pneumological phase ii rehabilitation in this group of patients is investigated. furthermore, the extent of these possible changes will be compared between post-covid patients who received respiratory muscle training and post-covid patients who did not receive respiratory muscle training. patients were not randomized but assigned to conditions based on medical criteria (e.g., initial respiratory muscle strength). the present project provides insight into participation- and function-related characteristics of a relatively new patient population, enables the observation of changes in these following pneumological phase ii rehabilitation and provides differentiated insights into the course of health-related parameters for specific subgroups (respiratory muscle training vs. no respiratory muscle training).


Eligibility criteria:
inclusion criteria: the study participants were regular patients in a rehabilitation centre. the data basis consists of secondary data collected during routine operation. exclusion criteria: -
validation of promising biomarker assays to assess their diagnostic performance characteristics

Conditions: Acute Febrile Illnesses

Summary: this project aims to evaluate the performance characteristics of rapid tests to differentiate bacterial from non-bacterial infection in febrile adults and children presenting at opds (outpatient departments) i.e.("fever triage assays") in three lmics. the evaluation will include a different commercial biomarker combinations as well as individual biomarkers to assess their individual or combined value in the target population. markers will be evaluated onsite in elisa or rdt format, as appropriate. further, this study aims to contribute to a centralized biobank of well-characterized specimens for use by ivd companies and academic institutions for the development and evaluation of emerging assays.


Eligibility criteria:
inclusion criteria: any non-severely ill subject presenting with acute fever defined as: temperature of more than 38°c at initial evaluation of less than 7 days of symptoms at presentation. inclusion criteria: * children 2-17 years of age * adults 18-65 years of age * signed written informed consent for study participation. for recruitment purposes, subjects will be classified into two groups, children and adults. for children, age \>2 years is the minimum cut-off, based on the amount of blood volume to be obtained in the study. who guidelines for allowable blood volume in 24 hours recommend that no more than 1-5% of total blood volume (75-80 ml/kg for older children) be obtained. applying the average weight of a 2 year old toddler =12 kg, the allowable blood volume to be drawn in 24 hours at 1-5% of the total blood volume is 9.6 - 48 ml . for minors, caregivers will provide informed consent. documented assent for children of 12 to 16 years of age will be required for their participation. exclusion criteria: * subjects who are felt to be in critical condition (based on clinician assessment or the presence of any general signs of critical illness as defined by who guidelines (for children: extensive vomiting, active seizure or recent history of seizures, altered mentation, inability to feed, or any of the severe imnci classifications; for adults: impending airway obstruction, central cyanosis, severe respiratory distress, feeble pulse, active seizure or recent history of seizures, or unconsciousness) because the target population for the study is non-severe febrile subjects. * subjects can only be enrolled once into the study.

Keywords: biomarker low and middle income countries fever antimicrobial resistance diagnostic